Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VY7523 in Early Alzheimer's Disease
NCT06874621Phase 2Active, not recruiting
- Sponsor
- Voyager Therapeutics
- Start
- Mar 2025
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of VY7523 in Alzheimer's disease (AD) (6 cohorts), sponsored by Voyager Therapeutics. Primary endpoint: Characterization of the safety and tolerability of VY7523 at 12 months. Started Mar 2025; status: active, not recruiting.
02
Drugs
VY7523
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06874621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06874621.